Table 2 Potential targets for anti-NETs in cancer
From: The role of neutrophil extracellular traps in cancer progression, metastasis and therapy
Target molecules | Mechanism | Agents | Cancer type | References |
|---|---|---|---|---|
NETs components | ||||
 DNA | DNA Degradation | Recombinant DNase | CRC | |
 NE | NE inhibitor | GW311616 | Leukemia | [116] |
 MPO | MPO inhibitor | PF-1355, ABAH, TX1 | – | |
 PAD4 | PAD4 inhibitor | GSK484, Cl-amidine | PDAC | |
Chemokines | ||||
 CXCR1 | CXCR1 inhibitor | SX-682, Reparixin | HNSCC, BC | |
 CXCR2 | CXCR2 inhibitor | SX-682, Reparixin, SB225002, AZ13381758 | HNSCC, BC, PDAC | |
 IL-8 | Anti-IL-8 | HuMab 10F8 | – | [122] |
 IL-17 | Anti-IL-17 | IL17 blockade | PDAC | [111] |
Transmembrane DNA receptor | ||||
 CCDC25 | Anti-CCDC25 | Anti-CCDC25 antibody | BC | [85] |
Cytokines | ||||
 TLR4 | TLR4 inhibitor | TAK-242 | CRC | [123] |
 TLR9 | TLR9 inhibitor | Hydroxychloroquine | – | [124] |
 TGF-β | TGF-β inhibitor | SB525334 | PDAC | [125] |